Ebolavirus and haemorrhagic syndrome

Sultan Qaboos University Medical Journal

Volumn 15, Issue 2, 2015, Pages e171-e176

  Matua, Gerald A ^a   Van Der Wal, Dirk M ^b   Locsin, Rozzano C ^c  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b UNIVERSITY OF SOUTH AFRICA   (South Africa)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Disease management; Ebola; Ebolavirus; Filoviridae; Hemorrhage; Hemorrhagic fever; Pathogenicity factors; Virulence

Indexed keywords

EBOLA VIRUS; FILOVIRIDAE; RNA VIRUSES;

EID: 84930061535     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: Major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 2011; 17:964–76. doi: 10.1111/j.1469-0691.2011.
2. Raabe VN, Borchert M. Infection control during filoviral hemorrhagic fever outbreaks. J Glob Infect Dis 2012; 4:69–74.doi: 10.4103/0974-777X.93765
3. Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease). From: www.cdc.gov/vhf/ebola/pdf/ebola-factsheet. pdf Accessed: Aug 2014.
4. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849–62.doi: 10.1016/S0140-6736(10)60667-8.
5. World Health Organization. Ebola Virus Disease: Fact sheet no. 103, 2014. From: www.who.int/mediacentre/factsheets/fs103/en/ Accessed: Aug 2014.
6. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 2010; 20:344–57.doi: 10.1002/rmv.661.
7. Hoenen T, Groseth A, Feldmann H. Current ebola vaccines. Expert Opin Biol Ther 2012; 12:859–72.doi: 10.1517/1 4712598.2012.685152.
8. Qiu X, Fernando L, Melito PL, Audet J, Feldmann H, Kobinger G, et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 2012; 6:e1575. doi: 10.1371/journal.pntd.0001575.
9. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Eds. Fields Virology. Philadelphia, USA: Lippincott, 2006. Pp. 1409–48.
10. Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Recent advances in Ebolavirus vaccine development. Hum Vaccin 2010; 6:439–49.doi: 10.1016/j.vaccine.2010.10.037.
11. Pourrut X, Délicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM. Spatial and temporal patterns of Zaire Ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis 2007; 15:S176–83.doi: 10.1086/520541.
12. Olival KJ, Islam A, Yu M, Anthony SJ, Epstein JH, Khan SA, et al. Ebola virus antibodies in fruit bats, Bangladesh. Emerg Infect Dis 2013; 19:270–3.doi: 10.3201/eid1902.120524.
13. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 1996; 2:321–5.doi: 10.3201/eid0204.960407.
14. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009; 5:e1000536.doi: 10.1371/journal.ppat.1000536.
15. Towner JS, Pourrut X, Albariño CG, Nkogue CN, Bird BH, Grard G, et al. Marburg virus infection detected in a common African bat. PLoS One 2007; 2:e764.doi: 10.1371/journal.pone.0000764.
16. Centre for Infectious Disease Research and Policy. Viral Hemorrhagic Fever: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis, 2009. From: www.cidrap.umn.edu/cidrap/content/bt/vhf/biofacts/vhffactsheet.html Accessed: Oct 2014.
17. Lamunu M, Lutwam, JJ, Kamugish, J, Opi A, Nambooze J, Ndayimirije N, et al. Containing haemorrhagic fever epidemic: The Ebola experience in Uganda (October 2000–January 2001). Int J Infect Dis 2004; 8:27–37. doi: 10.1016/j.ijid.2003.04.001
18. Kumar P, Clark M, Eds. Kumar and Clark’s Clinical Medicine, 5th ed. London, UK: Saunders Ltd, 2002.
19. Shoemaker T, MacNeil A, Balinandi S, Campbell S, Wamala JF, McMullan LK, et al. Reemerging Sudan Ebola virus disease in Uganda, 2011. Emerg Infect Dis 2012; 18:1480–3.doi: 10.3201/eid1809.111536.
20. Matua AG, Locsin RC. Conquering death from Ebola: Living the experience of surviving a life-threatening illness. In: Lee AV, Ed. Coping with Disease. New York, USA: Nova Science, 2005. Pp. 121–73.
21. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78:10370–7. doi: 10.1128/JVI.78.19.10370-10377.2004.
22. Ströher U, West E, Bugany H, Klenk HD, Schnittler HJ, Feldmann H. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 2001; 75:11025–33.doi: 10.1128/JVI.75.22.11025-11033.2001.
23. Volchkov V. Processing of the Ebola virus glycoprotein. Curr Top Microbiol Immunol 1999; 235:35–47.
24. Bonn D. Surviving Ebola infection depends on response. Lancet 1999; 353:1161.doi: 10.1016/S0140-6736(05)74383-X.
25. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, et al. Inflammatory responses in Ebola virusinfected patients. Clin Exp Immunol 2002; 128:163–8.doi: 10.1046/j.1365-2249.2002.
26. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5:423–6.doi: 10.1046/j.1365-2249.2002.01800.x.
27. Falzarano D, Geisbert TW, Feldmann H. Progress in filovirus vaccine development: Evaluating the potential for clinical use. Expert Rev Vaccines 2011; 10:63–77.doi: 10.1586/erv.10.152.
28. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999; 179:S18–23.doi: 10.1086/514298.
29. Sayburn A. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ 2014; 349:g5161.doi: 10.1136/bmj.g5161.
30. Zhang Y, Li D, Jin X, Huang Z. Fighting Ebola with ZMapp: Spotlight on plant-made antibody. Sci China Life Sci 2014; 987–8.doi: 10.1007/s11427-014-4746-7.
31. Mullard A. Experimental Ebola drugs enter the limelight. Lancet 2014; 384:649.doi: 10.1016/S0140-6736(14)61371-4.
32. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 1–8. doi: 10.1056/NEJMoa1411677.